logo
ADVERTISEMENT

AstraZeneca wades deeper into COVID therapeutics

The experimental antibody therapies are designed to target people with compromised immune systems.

image
by The Star

Africa17 May 2022 - 09:35
ADVERTISEMENT

In Summary


•The experimental antibody therapies are designed to target people with compromised immune systems.

•AstraZeneca signed a licence agreement with a small UK-based biotech company for a slate of COVID antibody therapies.

A company logo is seen at the AstraZeneca site in Macclesfield, Britain, May 11, 2021.

AstraZeneca has signed a licence agreement with a small UK-based biotech company for a slate of COVID antibody therapies, the Anglo-Swedish pharmaceutical giant said on Tuesday.

The experimental antibody therapies - developed by RK Bio, include those designed to target people with compromised immune systems - such as AstraZeneca's own antibody cocktail, Evusheld, which is already approved in multiple countries.

“WATCH: The latest videos from the Star”
ADVERTISEMENT